首页> 外文期刊>Journal of Experimental Pharmacology >Clevidipine resistance in a patient taking aripiprazole and methylphenidate
【24h】

Clevidipine resistance in a patient taking aripiprazole and methylphenidate

机译:服用阿立哌唑和哌醋甲酯的患者对克利地平的耐药性

获取原文
       

摘要

Abstract: Various factors may be responsible for blood pressure alterations during perioperative care. When these physiologic alterations require treatment, several therapeutic options are available. Clevidipine is an ultrashort-acting, intravenous L-type calcium channel antagonist of the dihydropyridine class. Anecdotal experience has demonstrated its efficacy in various clinical scenarios in the pediatric population. We report apparent resistance to the vasodilatory effects of clevidipine in a 13-year-old girl who presented for anesthetic care during posterior spinal fusion for neuromuscular scoliosis whose chronic medication regimen included aripiprazole and methylphenidate for the treatment of depression and attention-deficit/hyperactivity disorder. We discuss the potential interaction of aripiprazole and methylphenidate with the calcium channel antagonists and cellular mechanisms responsible for the resistance to the vasodilatory effects of clevidipine.
机译:摘要:围手术期护理过程中的多种因素可能导致血压变化。当这些生理变化需要治疗时,可以使用几种治疗方法。 Clevidipine是二氢吡啶类的超短效静脉内L型钙通道拮抗剂。轶事经验已证明其在儿科人群各种临床情况下的功效。我们报告了克利维地平在一个13岁女孩的神经血管性脊柱侧弯后路融合术中进行麻醉护理期间表现出的对血管舒张作用的明显抵抗,该患者的慢性药物治疗包括阿立哌唑和哌醋甲酯用于治疗抑郁症和注意力不足/多动障碍。我们讨论了阿立哌唑和哌醋甲酯与钙通道拮抗剂的潜在相互作用以及负责抵抗克维地平血管舒张作用的细胞机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号